US 20050180964 A1
A method for the prevention and treatment of fungal infections and, therefore, consequent invasive mycosis in mammalian and avian species is described. The invention comprises a combination of β-1,3(4)-endoglucanohydrolase, β-1,3(4)glucan, diatornaceous earth, mineral clay, and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to inhibit enteric fungal colonization in the gut and consequent mycosis. The invention described may be admixed with feeds or foods, incorporated into pelleted feeds or foods or administered orally to mammalian and avian species.
1. A composition comprising a combination of β-glucans, β-1,3(4)-endoglucanohydrolase, calcined diatomaceous earth, a mineral clay, and glucomannan is admixed in foods and animal feeds thereby inhibiting fungal growth in the food, feedstuff or digesta of mammalian and avian species, thereby reducing susceptibility to a mycotic colonization of the digestive tract and invasive mycoses.
2. The composition of
3. The composition of
4. The composition of
5. The composition of
6. The composition of
7. The composition of
8. The composition of
9. The composition of
10. The composition of
11. The composition of
12. The composition of
13. The composition of
14. The composition of
15. The composition of
U.S. Patent Documents
1. Field of the Invention
Methods and compositions for the inhibition of growth of infectious Aspergillus fumigatus and other pathogenic mycotic organisms in the gastrointestinal tract of mammalian and avian species.
Aspergillosis and mycotic infections. Aspergillosis is an acute systemic mycotic infection caused by Aspergillus sp. Species of Aspergillus known to cause an infection in mammals and avian species include Aspergillus fumigatus, Aspergillus flavis and Aspergillus niger. Infectious aspergillosis has been involved in mycotic abortions and related diseases (Jensen et al.,1991; McCausland et al., 1987). Medical literature contains numerous references indicating an increasing incidence of small bowel infarctions and coagulopathies in humans related to aspergillosis (Catalano et al., 1997; Prescott et al., 1992; Oshawa, 1991). Aspergillus fumigatus has also been implicated as a possible etiological agent in Jejunal Hemorrhage Syndrome in cattle, a new emerging disease that causes massive hemorrhaging of the small intestine (Puntenney et al., 2003). This disease also affects immunocompromised humans. Aspergillosis is also documented to cause a high incidence of abortions and pneumonia in cattle, a source of significant economic loss to the livestock industry (Puntenney et al., 2003).
Innoculation of an animal with Aspergillus sp. is commonly through ingestion of mold-contaminated feedstuffs due to improper storage or harvesting techniques, fecal contamination of feedstuffs from birds and rodents, and inhalation of Aspergillus spores from bedding material. The organism is especially effective in evasion of host animal defenses, by secretion of various lipid compounds, including fumigillin, fumitremorgin A, fumigaclavine, and gliotoxin at the infection site, impairing localized generation of complement factors C3a and C5a, thereby blocking recruitment of polymorphonuclear cells. Phagocytic cells normally follow the chemotactic gradient of complement components to the site of the infection, where engulfment and elimination of the organism from the animal occurs (Rhodes et al., 1992). The ability to sequester iron is a virulence factor for microorganisms. The binding of circulating iron to transferrin and lactoferrin, as well as the intercellular storage of iron, reduce levels of free iron below that required for microbial growth. Aspergillus sp. produces two major siderophores (high affinity iron binding compounds) that compete successfully with transferrin and lactoferrin to acquire iron for growth: N,N′,N″-triacetylfusarinine C and ferricrocin. Proteolytic digestion of transferrin may also be utilized as a means of iron acquisition. Iron is released from transferrin at pH<6 as a result of protonation of the iron binding site generally localized at infection site (Rhodes et al.,1992).
Aspergillus sp. produces two serine proteinases, elastinolytic and azocollytic enzymes, which break down tissue (Tomee and Kauffman, 2000; Frosco et al. ,1989). Proteinase enzyme production is tied to tissue invasiveness and facilitates entry from colonization site into the parenchyma. Hemorrhagic infarction (vascular blockage) and tissue necrosis may follow infection (Rhodes et al., 1992). After tissue invasion, dissemination via the bloodstream to other organs and the placenta occurs. Placentitis and subsequent abortions commonly result.
The fungal cell wall is composed of highly-branched β-1,3 glucans with linkages to chitin, galactomannan and a linear β-1,3/1,4 glucan (Fontaine, et al., 2000). Understanding of the structural biology of pathogenic fungi has aided the design of the invention. The efficacy of the invention is partly related to the addition of 1-1,3(4)-endoglucanohydrolase, which delays initiation of fungal growth via enzymatic degradation of cell wall components.
A second component of the invention, which functions in tandem with β-1,3(4)-endoglucanohydrolase, is β-1,3 glucan. The role of β-1,3 glucan in macrophage activation and response to pathogens is well documented in the literature (Czop, et al., 1985, Xia et al,1999). Upon entering the aqueous conditions of the digestive tract, the large glucan molecules in the invention, via the enzymatic activity of β-1,3(4)-endoglucanohydrolase, are effectively reduced to smaller moieties that may be accepted by macrophage receptors, stimulating immunological activation. Other components of the invention, diatomaceous earth and aluminosilicate, are capable of binding toxic lipid compounds which are secreted by pathogenic fungi. These toxins, if not bound, effectively block release of complement factors required for macrophage response to colonization.
The feeding of a combination of β-1,3(4)-endoglucanohydrolase, β-glucan, calcined diatomaceous earth (hereafter identified as diatomaceous earth; SiO2), glucomannan, and mineral clay, such as aluminum silicate, montmorillonite clay, bentonite or zeolite, has been shown to delay growth of A. fumigatus for a period of several hours in laboratory cultures and clinical trials thereby effectively minimizing the ability of Aspergillus to inhibit complement factor production thereby allowing an intact immune system to respond to fungal colonization.
The object of the present invention is to provide a novel and previously unknown method for inhibition of the colonization of the digestive tracts and consequent systemic infection (mycosis) of mammalian and avian species by various pathogenic microorganisms (specifically pathogenic fungal organisms). The invention may be applied to, but not limited to, in situ inhibition of the enteric growth and mycosis caused by various pathogenic microorganisms including Aspergillus, Aureobasidium, Candida, Eupenicillium, Eurotium, Fusarium, Mucor, Penicillium, Rachihorskiomyces and other genera which comprise the fungal taxonomic classification (Kingdom Fungi) as outlined by Alexopolous et al., 1996.
A further object of this invention is to provide a method for inhibition of pathogenic microbial growth in situ and, consequently, in blood and to thereby minimize or obviate morbidities and mortalities caused by, but not limited to, pathogenic fungi with a preparation comprising a combination of β-1,3(4)-endoglucanohydrolase, β-glucan, diatomaceous earth, glucomannan, and mineral clay, such as aluminum silicate, montmorillonite clay, bentonite or zeolite.
Another object of the invention is to provide a composition comprising a combination of β-1,3(4)-endoglucanohydrolase, β-glucan, diatomaceous earth, mineral clay, and glucomannan, which additively minimizes growth and, thereby, reduces mycotic potential of pathogenic fungi in the gastrointestinal tracts of mammalian and avian species.
Additional objects, advantages and novel features of the invention will be set forth, in part, in the description that follows and will, in part, become apparent to those skilled in the art upon examination of the following or may be learned with the practice of the invention. To achieve the foregoing and other objects, and in accordance with the purposes of the present invention as described herein, a novel method is described for the inhibition of growth of pathogenic fungal organisms which typically underlie enteric-based and mycotic morbidities and mortalities of mammalian and avian species. In particular, this invention minimizes or eliminates the colonization of the gastrointestinal tract by pathogenic fungi, reduces the populations of pathogenic organisms in blood and thereby minimizes or eliminates pathologies directly caused by and indirectly caused by this colonization. The invention comprises a mixture of β-1,3(4)-endoglucanohydrolase, β-glucan, diatomaceous earth, mineral clay, and glucomannan. The diatomaceous earth is standard commercial grade available from a variety of sources. The β-1,3(4)-endoglucanohydrolase is produced from submerged fermentation of a strain of Trichoderma longibrachiatum. The β-1,3(4)glucan and glucomannan are derived from a commercial product and are an extraction from any of a number of yeast organisms. The mineral clay product is a standard commercial grade (examples include, but are not limited to, montmorillonite clay, bentonite and zeolite). Extractions and productions of diatomaceous earth, yeast cell wall extract and mineral clay are well known in the art and commercially-available.
The compositions which are provided by the invention can be fed to any mammalian or avian species including, but not limited to, bovine, equine, ovine, caprine and avian species. When admixed with the feed or food or fed as a supplement, the invention minimizes or eliminates the growth of pathogenic fungi in the gut thereby allowing colonization of the gut with non-pathogenic species. The invention also minimizes or eliminates invasion of the blood compartment by pathogenic fungi. The invention thereby minimizes or eliminates the manifestations of the pathologies typically associated with enteric fungal infections. Administration of the product may be used as a prophylactic (i.e., to prevent colonization and growth of pathogenic fungal species in the gut of mammalian or avian species), as an additive to feeds or foods infected with pathogenic fungi or as a preferred method to treat and thereby minimize or eliminate an existing, diagnosed or non-diagnosed, enteric fungal infection and mycoses. Application of the invention as described herein and via the specific and novel mechanisms described herein will minimize and possibly eliminate manifestations of enteric fungal infections and, consequently, mycotic infections including, but not limited to, the following genera: Aspergillus, Aureobasidium, Candida, Eurotium, Fusarium, Mucor, Penicillium and Rachiborskiomyces. Application of the invention as described herein will also minimize or possibly eliminate manifestations associated with the presence of pathogenic fungal organisms, as identified above, in food or feed of mammalian and avian species.
The accompanying drawings and photographs which are incorporated into the following “Detailed Description of the Invention” form part of the specification and illustrate several aspects of the present invention and, together with the Detailed Description, serve to explain the details of the invention. In the following section:
The present invention is based on the novel discovery that a combination of β-1,3(4)-endoglucanohydrolase, β-1,3(4)glucan, diatomaceous earth, mineral clay, and glucomannan effectively inhibit the growth of pathogenic fungal species and thereby reduce or eliminate the direct or indirect negative consequences which accrue to the host mammalian or avian organism.
The β-1,3(4)-endoglucanohydrolase is from a commercial source and is produced from submerged fermentation of a strain of Trichoderma longibrachiatum.
The diatomaceous earth is prepared by methods commonly known in the art. It is available as a commercially-available acid-washed, product with 95% silica (SiO2) and with its remaining components not assayed but consisting primarily of ash (minerals) as defined by the Association of Analytical Chemists (AOAC, 2002).
The yeast cell wall extract is prepared by a method commonly known in the art. It is a commercial source of β-1,3(4)glucan and glucomannan derived from primary inactivated yeast (Saccharomyces cerevisiae) with the following chemical composition:
The mineral clays (aluminosilicates) used in this invention may be fulfilled by any of a variety of commercially-available clays including, but not limited to, montmorillonite clay, bentonite and zeolite.
In a preferred embodiment of the invention, β-1,3(4)-endoglucanohydrolase, diatomaceous earth, yeast cell wall extract and mineral clay are combined at 0.05-3%, 1-40%, 1-20% and 40-92%, respectively. In a preferred composition, β-1,3(4)-endoglucanohydrolase, diatomaceous earth, yeast cell wall extract and mineral clay are combined at 0.1-3%, 5-40%, 2-10% and 40-80%, respectively. In an especially preferred embodiment of the invention, β-1,3(4)-endoglucanohydrolase, diatomaceous earth, yeast cell wall extract and mineral clay are combined at 0.2-3%, 30-40%, 4-6% and 50-65%, respectively. The preferred physical form of the invention is a dry, free-flowing powder which is suitable for direct inclusion into a feed, food product or as a supplement to a total mixed ration or diet.
The compositions provided by the present invention may be incorporated directly into commercially-available feeds or food products or fed as supplements to commercially-available feeds or food products. The composition contained in the present invention may be fed to any mammalian or avian species. The methods of the invention comprise reducing the growth and associated mycosis caused by enteric infections of pathogenic fungal organisms in the gut of mammalian and avian species. When incorporated directly into feeds, the present invention may be added to feeds in amounts ranging from 0.1 to 5 kg per ton of feed. In an especially preferred composition, the invention may be added to feeds in amounts ranging from 1-2 kg per ton of feed.
The composition contained in the present invention may be added to animal feedstuffs or to foods in amounts ranging from 0.0125% to 2% by weight of feed. In a preferred embodiment, the composition is added to animal feedstuffs or to food in amounts from 0.0625% to 1% by weight of feed. In an especially preferred embodiment, the invention is added in amounts from 0.125% to 0.5% by weight of feed.
Alternatively, the composition contained in the present invention may be fed directly to mammalian or avian species as a supplement in amounts 0.016 grams/kg to 0.37 grams/kg of live body weight per day. In an especially preferred embodiment, the invention may be provided to mammalian and avian species in amounts of 0.10 grams/kg to 0.20 grams/kg of body weight per day. One of skill and art can appreciate that the amount of the invention fed can vary depending upon the animal species, size of the animal and type of the feedstuff to which the invention is added.
The novel methods of this invention comprise the ability of a combination of β-1,3 (4)-endoglucanohydrolase, diatomaceous earth, yeast cell wall extract and clay to inhibit the enteric growth and mycosis caused by various pathogenic fungal genera which include, but are not limited to, Aspergillus, Aureobasidium, Candida, Eurolium, Fusarium, Mucor, Penicillium and Rachiborskiomyces sp. The benefits resulting from the application of the invention to mammalian species include, but are not limited to, reduced death losses, reduced incidence of mycotic abortion, reduced incidence of jejunal hemorrhage syndrome (dead gut syndrome), reduced incidence of scouring (diarrhea), improved growth rate, improved efficiency of growth, improved milk production, improved efficiency of milk production and reduced somatic cell counts in milk products (dairy animals). The benefits from the application of the invention to avian species include, but are not limited to, reduced death losses, improved growth and egg production, improved fertility, and reduced incidence of enteric diseases.
The following are intended to be illustrative of the invention, and are not to be considered restrictive of the scope of the invention as otherwise described herein.
The following novel experiment documents the presence of mold spores or conidia in the feed, jejunal contents and jejunal wall of a Holstein dairy cow which died in 2002 from jejunal hemorrhage syndrome (dead gut syndrome).
Samples of feed, jejunal contents and jejunal tissue were homogenized in a Polytron and serial dilutions (1 ml) of these samples were applied to a Petrifilm® mold count plate. The feed sample was centrifuged following homogenization to generate a particulate fraction and a soluble fraction. The density of mold counts in each of these samples is shown in Table 1.
The data indicate the presence of mold in feed and the gut. Of interest, the mold sample preferentially localized into the jejunal wall, a characteristic of Aspergillus fumigatus. These data indicated potential for the fungal infection to underlie the etiology which led to death of the animal.
The following experiment documents a novel discovery in which we determined that fungi can colonize the gut, invade the blood and produce a mycotic condition which can result in jejunal hemorrhage, mycotic abortion and death of dairy animals. To complete this study, several novel steps were undertaken:
The sequence of Aspergillus fumigatus 18S small ribosomal subunit gene was determined from existing literature (Jaeger et al., 2000) and used to design DNA primers for polymerase chain reaction (PCR) analysis of the presence of Aspergillus DNA in the gut, tissues and blood of cows exhibiting mycotic abortion or which had died from jejunal hemorrhage. Two sets of primers were prepared: a primary pan-fungal set which amplified all fungal DNA and a “nested set” which specifically-amplified and detected Aspergillus genera (Jaeger et al., 2000).
Additional primers (from the 18S gene) were designed for Sybr-Green analysis (real-time quantitative PCR) to allow for the determination of the mold DNA concentration (mold “burden”) in blood of cows which had mycotic abortions or which had died from jejunal hemorrhage syndrome.
Using the DNA primers designed in Step 1 (above) we determined that cows afflicted with jejunal hemorrhage syndrome or which displayed mycotic abortions exhibited high levels of Aspergillus mold counts in jejunal wall and blood. Using our novel real-time Sybr-Green quantification protocol (Step 2, above) we determined that the mold burden in cows which had either died from jejunal hemorrhage syndrome or which had displayed incidence of mycotic abortion were extremely high. Control (asymptomatic) cows did not harbor fungal DNA. Instead, via sequencing, we have detected other non-pathogenic fungal species (e.g., Cladosporium) at low concentrations. This has led us to conclude that lower levels of Aspergillus infection (mycosis) result in abortion (known as “mycotic abortion”) whereas exceedingly high levels result in death of the infected animal. Whether or not death results from a direct effect of fungal infection or, instead, from secondary (indirect) bacterial infections (e.g., Clostridium sp.) has not been determined.
The following novel experiment illustrates the ability of a mixture of clay and β-1,3(4)glucan/glucomannan (95.6% and 4.4%, respectively) to inhibit the growth of Aspergillus fumigatus in culture. A. fumigatus culture was derived from a local corn grain sample and applied as a streak to a culture plate containing Sabouraud dextrose agar medium supplemented with chloramphenicol and gentimycin (to inhibit bacterial growth). Drops (50 μl) of sodium-aluminum silicate clay combined with β-1,3(4)glucan and glucomannan (40 mg/ml: 95.6% clay, 4.4% β-1,3(4)glucan and glucomannan) were applied to the A. fumigatus streaks and the growth of the mold culture was evaluated following 42 hours of culture at 27° C. The mold culture at 42 hours is shown as a zigzag pattern of white mold with spreading mycelia (see Appended
This novel experiment shows that additions of the mineral clay, β-1,3(4)glucan and glucomannan mixture (95.6% clay, 4.4% β-1,3(4)glucan and glucomannan) effectively inhibit the growth of Aspergillus fumigatus. The inhibition of fungal growth with these combined ingredients, represents a portion of the mechanism of action which we submit as a mechanism of action for products in the treatment and prevention of mycotic diseases in mammalian and avian species.
Aspergillus was inoculated into 10 ml of Sabouraud dextrose broth supplemented with chloramphenicol and gentimycin (to inhibit bacterial growth). In addition, various amounts of a combination of mineral clay:β-1,3(4)glucan and glucomannan were added directly to cultures to establish the effects of these compounds on the growth of the Aspergillus culture. The density of cells was utilized as an index of A. fumigalus cell number and density was monitored using a spectrophotometer (wavelength was 530 nm).
In control cultures (i.e., A. fumigatus with no additions of the three components of the invention), we typically observed a long lag phase (see appended
Of interest, the transit time of digesta in an adult bovine animal is 48-72 hours. The poorer growth conditions which A. fumigatus would find in the bovine digestive tract (i.e., due to competition with other microbial species, less growth substrate and less oxygen) would most likely alter its growth in such a manner that a delay in log-phase growth could result in loss of the infectious organism in the feces before it has opportunity to rapidly proliferate. Hence, we propose that the delay in the log-phase fungal growth caused by the presence of a 95.6% mineral clay with 4.4% β-1,3(4)glucan and glucomannan mixture effectively reduces the degree of colonization of the gut which may be caused by Aspergillus and other fungal genera and thereby reduces the harmful direct, and possibly indirect, effects of an Aspergillus infection or infection by other pathogenic fungal species.
This novel experiment documents the ability of diatomaceous earth to inhibit the growth of A. fumigatus in culture.
Similar to Example 4, diatomaceous earth was added to cultures of A. fumigatus which had been supplemented with chloramphenicol and gentimycin (to inhibit bacterial growth). A control sample was prepared to study fungal growth in the absence of diatomaceous earth. In addition, various levels of diatomaceous earth (5, 50, 250, 500, 1000 and 5000 μg/10 ml culture) were added to A. fumigatus cultures to determine its effects on fungal growth. Culture conditions were identical to those outlined in Example 4.
This novel experiment documents the additive ability of a 3-way combination of diatomaceous earth, mineral clay and β-1,3(4)glucan and glucomannan mixture to effectively inhibit fungal growth.
In this experiment, Aspergillus fumigatus was cultured as described in previous examples. The effects of adding a mixture of all three ingredients on growth of A. fumigatus were studied. The mineral clay: β-1,3(4)glucan and glucomannan mixture delayed entry into log phase growth (as described in Examples 2-5). Diatomaceous clay (50 μg/10 ml of culture) in combination with mineral clay: β-1,3(4)glucan and glucomannan mixture (500 μg/10 ml culture) inhibited growth of the Aspergillus culture (i.e., a longer delay in entry into log-phase growth; see appended
This novel experiment documents the ability of β-1,3(4)-endoglucanohydrolase, alone and in combination with the other components of the invention, to markedly inhibit growth of A. fumigatus in liquid culture. In this experiment, the abilities of β-1,3(4)-endoglucanohydrolase alone (100 tμ/ml) and a combination of β-1,3(4)-endoglucanohydrolase (100 μg/ml) and a mixture of diatomaceous earth, mineral clay and β-1,3(4)glucan/glucomannan (100 μg/ml) were combined and their effects on fungal growth (as described above) were assessed. The β-1,3(4)-endoglucanohydrolase alone was unable to reduce fungal growth (
These results show that the composition of the invention (i.e., mineral clay, yeast cell wall extract, diatomaceous earth and β-1,3(4)-endoglucanohydrolase) is capable of a previously-undescribed effect of inhibiting growth of pathogenic fungal species; species which have documented adverse effects on morbidities and mortalities of mammalian and avian species. The combination of products reduces growth of pathogenic fungi in the gut of mammalian and domestic species and thereby prevents the invasion and colonization of the blood compartment (mycosis) and represents a mixture which is flowable in easily incorporated into feed products and food products. The invention specifically prevents fungal-based septicemia and the deleterious direct and indirect effects resulting thereof The present invention was effective in achieving its inhibitory effects under growth conditions which might be found in mammalian and avian digestive systems where nutrients, moisture, oxygen and elevated temperatures are provided by the host.
The foregoing description of the preferred embodiment of the invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Obvious modifications or variations are possible in light of the above illustrations. The embodiment was chosen and described to provide the best illustration of the principles of the invention and its practical application to thereby enable one of ordinary skill in the art to utilize the invention in various embodiments and with modifications as are suited to the particular use contemplated. All such modifications and variations are within the scope of the invention as determined by the appended claims when interpreted in accordance with the breadth to which they are fairly, legally and equitably entitled.